Trials / Conditions / Primary Hyperoxaluria

Primary Hyperoxaluria

23 registered clinical trials studyying Primary Hyperoxaluria — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Baby Detect : Genomic Newborn Screening NCT05687474	Centre Hospitalier Universitaire de Liege	—
Recruiting	Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria NCT05843851	Cystinose Stiftung	N/A
Completed	Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function NCT05001269	Dicerna Pharmaceuticals, Inc., a Novo Nordisk company	Phase 2
Unknown	Phenotyping of Primary Hyperoxaluria NCT05107830	University Hospital, Strasbourg, France	—
Completed	A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 NCT04152200	Alnylam Pharmaceuticals	Phase 3
Completed	Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria NCT03819647	Biocodex	Phase 2
Completed	A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 NCT03905694	Alnylam Pharmaceuticals	Phase 3
Completed	Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia NCT03391804	Allena Pharmaceuticals	Phase 2
Completed	An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria NCT03350451	Alnylam Pharmaceuticals	Phase 2
Completed	A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria NCT03116685	OxThera	Phase 3
Completed	Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria NCT03392896	Dicerna Pharmaceuticals, Inc., a Novo Nordisk company	Phase 1
Completed	Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialys NCT02000219	OxThera	Phase 2
Completed	Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria NCT02012985	OxThera	Phase 1 / Phase 2
Completed	Primary Hyperoxaluria Mutation Genotyping/Phenotyping NCT02340689	Mayo Clinic	—
Completed	Health-related Quality of Life in Rare Kidney Stone NCT02124395	NYU Langone Health	—
Recruiting	Rare Kidney Stone Consortium Biobank NCT02026388	Mayo Clinic	—
Completed	Phase 2/3 Oxabact Study NCT01037231	OxThera	Phase 2 / Phase 3
Recruiting	National Registry of Rare Kidney Diseases NCT06065852	UK Kidney Association	—
Completed	Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluri NCT00638703	OxThera	Phase 2 / Phase 3
Completed	Primary Hyperoxaluria Mutation Genotyping NCT00589225	Mayo Clinic	—
Withdrawn	International Registry for Primary Hyperoxaluria NCT00875823	Mayo Clinic	—
Recruiting	Rare Kidney Stone Consortium Patient Registry NCT00588562	Mayo Clinic	—
Approved For Marketing	Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1 NCT04125472	Alnylam Pharmaceuticals	—